This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Clinical research and practice in neurology are rapidly changing with the development and introduction of new therapies. Within the past 3 years, specific treatments have been introduced for disorders that were previously considered untreatable, including ischemic stroke, amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer's disease. In addition, a flood of new therapeutic agents, some representing novel pharmacologic classes, are being introduced for the treatment of epilepsy and Parkinson's disease. After years of slow discovery of therapeutic agents, this veritable deluge of therapeutic options may be overwhelming for clinicians. Moreover, there is a vast array of other interventions currently in development that will complement the compounds that are already marketed. Neurology has always sought to publish information on new treatments; however, we intend to take additional steps to make experimental therapeutics a major focus of the journal. The development and reporting of new treatments will have a critical impact on the lives of our patients, the practice of neurology, and the planning of future basic and clinical research.
To make Neurology as useful as possible to authors and clinicians, we will expedite publication of important clinical trials (see preceding editorial) and publish well-designed and conducted clinical trials regardless of the outcome of the study. Journals have sometimes had a bias toward publishing "positive" (regarding therapeutic benefit) studies while relegating "negative" studies to appear as abstracts or to less available venues. "Positive" studies with methodologic deficiencies have been prominently published, while "negative" studies with more methodologic rigor have not. We will focus on publishing more rigorously designed studies, specifically those using a control group, randomization, and a method of blinding, instead of publishing studies with weaker designs. Uncontrolled, nonrandomized, unblinded studies will be considered for publicationas Brief Communications or Clinical/Scientific Notes but will rarely be appropriate for publication as full-length articles. Such …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
